SK Bioscience KRX:302440KOSPI
SK바이오사이언스 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked0since Sep 11
In Q2 2026, SK Bioscience reported revenue of ₩156bn, down 3.8% year on year, and an operating loss of ₩15.7bn. SK Bioscience (SK바이오사이언스) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
SK Bioscience quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩156bn | -3.8% | −₩15.7bn | −₩14.1bn |
| Q1 2026 | ₩169bn | +9.1% | −₩44.5bn | −₩36.2bn |
| Q4 2025 derived | ₩184bn | +17.4% | −₩51.6bn | −₩56.4bn |
| Q3 2025 | ₩151bn | +144.6% | −₩19.4bn | ₩21.1bn |
| Q2 2025 | ₩162bn | +504.5% | −₩37.4bn | −₩16.8bn |
| Q1 2025 | ₩155bn | +594.0% | −₩15.1bn | −₩4.1bn |
| Q4 2024 derived | ₩157bn | +73.1% | −₩50.8bn | −₩2.7bn |
| Q3 2024 | ₩61.6bn | -73.4% | −₩39.6bn | −₩22.3bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
SK Bioscience top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest SK Bioscience news Korean headlines
No articles yet.